Membrane-To-Nucleus Signaling Links Insulin-Like Growth Factor-1- and Stem Cell Factor-Activated Pathways
Open Access
- 7 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e76822
Abstract
Stem cell factor (mouse: Kitl, human: KITLG) and insulin-like growth factor-1 (IGF1), acting via KIT and IGF1 receptor (IGF1R), respectively, are critical for the development and integrity of several tissues. Autocrine/paracrine KITLG-KIT and IGF1-IGF1R signaling are also activated in several cancers including gastrointestinal stromal tumors (GIST), the most common sarcoma. In murine gastric muscles, IGF1 promotes Kitl-dependent development of interstitial cells of Cajal (ICC), the non-neoplastic counterpart of GIST, suggesting cooperation between these pathways. Here, we report a novel mechanism linking IGF1-IGF1R and KITLG-KIT signaling in both normal and neoplastic cells. In murine gastric muscles, the microenvironment for ICC and GIST, human hepatic stellate cells (LX-2), a model for cancer niches, and GIST cells, IGF1 stimulated Kitl/KITLG protein and mRNA expression and promoter activity by activating several signaling pathways including AKT-mediated glycogen synthase kinase-3β inhibition (GSK3i). GSK3i alone also stimulated Kitl/KITLG expression without activating mitogenic pathways. Both IGF1 and GSK3i induced chromatin-level changes favoring transcriptional activation at the Kitl promoter including increased histone H3/H4 acetylation and H3 lysine (K) 4 methylation, reduced H3K9 and H3K27 methylation and reduced occupancy by the H3K27 methyltransferase EZH2. By pharmacological or RNA interference-mediated inhibition of chromatin modifiers we demonstrated that these changes have the predicted impact on KITLG expression. KITLG knock-down and immunoneutralization inhibited the proliferation of GIST cells expressing wild-type KIT, signifying oncogenic autocrine/paracrine KITLG-KIT signaling. We conclude that membrane-to-nucleus signaling involving GSK3i establishes a previously unrecognized link between the IGF1-IGF1R and KITLG-KIT pathways, which is active in both physiologic and oncogenic contexts and can be exploited for therapeutic purposes.Keywords
This publication has 63 references indexed in Scilit:
- Nuclear IGF1R is a transcriptional co‐activator of LEF1/TCFEMBO Reports, 2012
- Cellular Changes in Diabetic and Idiopathic GastroparesisGastroenterology, 2011
- Kitlow Stem Cells Cause Resistance to Kit/Platelet-Derived Growth Factor α Inhibitors in Murine Gastrointestinal Stromal TumorsGastroenterology, 2010
- Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplificationInternational Journal of Cancer, 2010
- Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)Trends in Immunology, 2010
- Oncogenic and ligand‐dependent activation of KIT/PDGFRA in surgical samples of imatinib‐treated gastrointestinal stromal tumours (GISTs)The Journal of Pathology, 2008
- Progenitors of Interstitial Cells of Cajal in the Postnatal Murine StomachGastroenterology, 2008
- Chromatin Modifications and Their FunctionCell, 2007
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007
- Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanismBritish Journal of Cancer, 2006